Rhythm Pharmaceuticals (RYTM) Non Operating Income (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Non Operating Income data on file, last reported at -$1.7 million in Q1 2026.

• Non Operating Income for Q1 2026 came in at -$1.7 million, up 29.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.0 million (down 44.82% YoY), and the FY2025 annual result was $1.3 million, down 75.91% from the prior year.
• Non Operating Income retreated to -$1.7 million in Q1 2026 per RYTM's latest filing, from $4.8 million in the prior quarter.
• Over five years, Non Operating Income peaked at $8.7 million in Q2 2024 and troughed at -$2.4 million in Q1 2025.
• A 5-year average of $576764.7 and a median of -$27000.0 in 2023 frame the typical range for Non Operating Income.
• On a YoY basis, Non Operating Income climbed as much as 51252.94% in 2024 and fell as far as 4288.89% in 2024.
• A 5-year view of Non Operating Income shows it stood at -$1.6 million in 2022, then surged by 135.11% to $559000.0 in 2023, then soared by 403.22% to $2.8 million in 2024, then soared by 71.24% to $4.8 million in 2025, then slumped by 135.37% to -$1.7 million in 2026.
• Business Quant data shows RYTM's Non Operating Income at -$1.7 million in Q1 2026, $4.8 million in Q4 2025, and $274000.0 in Q3 2025.